We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Concussion Leading to Long Term Cognitive Disability May Be Diagnosed by a Simple Blood Test

By LabMedica International staff writers
Posted on 02 Dec 2013
Print article
The blood level of the protein SNTF (calpain-cleaved alphaII-spectrin N-terminal fragment) measured on the day of a computed tomography (CT)-negative mild traumatic brain injury was used to identify a subset of patients at risk of white matter damage and persistent disability.

Mild traumatic brain injury (mTBI), or concussion, is not typically associated with abnormalities on CT. Nevertheless, it causes persistent cognitive dysfunction for many patients. Therefore, new prognostic methods for mTBI are needed to identify at risk cases, especially at an early and potentially treatable stage.

Investigators at University of Pennsylvania (Philadelphia, USA) in conjunction with colleagues at the Baylor College of Medicine (Houston, TX, USA) identified a new blood biomarker that correctly predicted which concussion victims had suffered white matter structural damage and persistent cognitive dysfunction following an mTBI.

The investigators evaluated blood samples and diffusion tensor images from a group of 38 individuals aged from 15 to 25 years who were participants in a larger mTBI study. Seventeen patients had sustained a head injury caused by blunt trauma, acceleration, or deceleration forces; 13 had an orthopedic injury (OI); and eight were healthy, uninjured, demographically matched controls.

Results revealed that SNTF levels were at least twice the lower limit of detection in 7 of 17 mTBI cases and in 3 of 13 OI cases, but in none of the control subjects. Increased plasma SNTF on the day of injury correlated significantly with cognitive impairment that persisted for at least three months, both across all study participants and also among the mTBI cases by themselves.

"The blood test identified SNTF in some of the orthopedic injury patients as well, suggesting that these injuries could also lead to abnormalities in the brain, such as a concussion, that may have been overlooked with existing tests," said senior author Dr. Douglas Smith, professor of neurosurgery at the University of Pennsylvania. "SNTF as a marker is consistent with our earlier research showing that calcium is dumped into neurons following a traumatic brain injury, as SNTF is a marker for neurodegeneration driven by calcium overload."

"New tests that are fast, simple, and reliable are badly needed to predict who may experience long-term effects from concussions, and as new treatments are developed in the future, to identify who should be eligible for clinical trials or early interventions," said first author Dr. Robert Siman, professor of neurosurgery at the University of Pennsylvania. "Measuring the blood levels of SNTF on the day of a brain injury may help to identify the subset of concussed patients who are at risk of persistent disability."

The paper was published in the November 18, 2013, online edition of the journal Frontiers in Neurology.

Related Links:

University of Pennsylvania
Baylor College of Medicine


Gold Member
Flocked Fiber Swabs
Puritan® Patented HydraFlock®
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Cytomegalovirus Real-Time PCR Test
Quanty CMV Virus System
New
Epstein-Barr Virus Test
Mononucleosis Rapid Test

Print article

Channels

Clinical Chemistry

view channel
Image: The GlycoLocate platform uses multi-omics and advanced computational biology algorithms to diagnose early-stage cancers (Photo courtesy of AOA Dx)

AI-Powered Blood Test Accurately Detects Ovarian Cancer

Ovarian cancer ranks as the fifth leading cause of cancer-related deaths in women, largely due to late-stage diagnoses. Although over 90% of women exhibit symptoms in Stage I, only 20% are diagnosed in... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The new algorithms can help predict which patients have undiagnosed cancer (Photo courtesy of Adobe Stock)

Advanced Predictive Algorithms Identify Patients Having Undiagnosed Cancer

Two newly developed advanced predictive algorithms leverage a person’s health conditions and basic blood test results to accurately predict the likelihood of having an undiagnosed cancer, including ch... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.